FDA Approves Updates to Lilly’s Humalog® (insulin lispro injection [rDNA origin]) Label
Submitted by Lilly Diabetes for inclusion in this website
For Release: Immediately
Refer to: Jacqueline K. Giovanoni, Lilly Diabetes, Advocacy and Professional Relations
Lilly Corporate Center
Indianapolis, IN 46285
317.277.3922 (O)
317.358.5824 (M)
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Update for Insulin Pump Use Provides an Additional Option for Children With Type 1 Diabetes and Extends Amount of Time People Can Use and Store Humalog Insulin in Their Pumps

